Skip to main content
Premium Trial:

Request an Annual Quote

Nic Austin, Matt Hahn, James Collins, Jeffrey Besterman, Jeffrey Hanke, Stuart Kaufmann, Hiroaki Kitano, Christophe Lengauer, Matej Oresic, Hans Winkler

Premium
Nic Austin has resigned as vice president of research and development at Accelrys, the company disclosed in a filing with the US Securities and Exchange Commission this week.
 
Matt Hahn will replace Austin as VP of R&D. Hahn was a founder of Scitegic, which Accelrys acquired in 2004. He then served as chief science and technology officer at Accelrys until October 2006, when he was promoted to VP of platform strategy and technologies.
 
According to the filing, Austin will remain employed until June 30 “to assist with a transition of his responsibilities.”
 
Upon leaving the firm, Austin will receive £94,000 ($187,000) and will remain eligible to receive a bonus from the company’s 2008 fiscal year management incentive plan.
 

 
Gene Network Sciences has named James Collins, professor of biomedical engineering at Boston University and co-director of BU’s Center for Biodynamics, as its chief scientific officer, a newly created position.
 
In addition to his position at BU, Collins is the founder and former CSO of systems biology firm Cellicon Biotechnologies
 
GNS has also formed a new scientific advisory board, which Collins will chair. Members of the SAB include Jeffrey Besterman, executive vice president of R&D and CSO of Methylgene; Jeffrey Hanke, VP of cancer care discovery at AstraZeneca; Stuart Kaufmann, chair of biocomplexity and informatics at the University of Calgary; Hiroaki Kitano, director of Sony Computer Science and president of the Institute for Systems Biology; Christophe Lengauer, executive director of cancer discovery at Novartis; Matej Oresic, principal investigator of systems biology and bioinformatics at Finland’s VTT Technical Research Center; and Hans Winkler, senior director of functional genomics at Johnson & Johnson

Filed under

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.